glp 1 receptor agonists incretin mimetics A Brief Review of Intended for the Management of Diabetes and Associated Comorbidities[v1] GLP-1 actions and target organs.

Gastrointestinal adverse events were predominantly limited to initial dosing, while dose escalation resulted in lower discontinuation rates owing to these adverse events than among patients who remained on the starting dose

Kuznetsova, A., Brockhoff, P

So-called non-responders are people who lose less than 5 percent of their body weight after roughly six months of treatment on the highest tolerated dose

A meta-regression study suggested a linear relationship between HbA1c reduction and MACE risk in patient with arGLP-1.89 Publication on mediation analyses also suggest that cardiovascular benefit could be mediated in part by effects on HbA1c, on blood pressure or reduction in urine albumin-creatinine ratio90,91 (see below), as well as by their effect on lipid profile.81 However, in subgroup analyses of cardiovascular safety studies, baseline HbA1c, weight, previous cardiovascular disease, or renal function did not predict the beneficial effects of these drugs on MACE,87 so other mechanisms, such as the previously mentioned anti-inflammatory, antifibrotic, antiatherogenic, vasodilator, or endothelial function-enhancing effects, have been suggested to influence the cardiovascular benefit of these drugs29,78 (Fig

But do you think that's a likely path for these

Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease